anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Distinguishing between organ-confined disease and extraprostatic extension (EPE) is crucial for the treatment of patients with prostate cancer. EPE is associated with an increased risk of biochemical recurrence, positive surgical margins, and metastatic disease. An MRI-based EPE scoring system was developed by Mehralivand in 2019; however, it has not been adopted in the Urology community. The purpose of this study is to evaluate the association of MRI-based EPE scoring with the pathologic EPE (pEPE) after radical prostatectomy. Methods: We conducted a retrospective review on a prospectively collected database of male patients who underwent a prostate MRI with EPE scoring by a trained genitourinary radiologist and subsequent robotic radical prostatectomy at our institution from September 2020 to December 2022. The associations between MRI EPE (mEPE) score and the presence of EPE on surgical pathology (pEPE) were examined using multivariable logistic regression. Results: A total of 194 patients met inclusion criteria with a median age of 63 years and prostate specific antigen (PSA) 7 ng/mL. Among those with mEPE score 3, 96% had pEPE. Those patients with an mEPE score ≥2 had an increased risk of pEPE compared with those with mEPE score 0 (odds ratio 3.79; 95% confidence interval 1.28-11.3) Furthermore, those with an mEPE score 3 were significantly more likely to have pEPE compared with those with mEPE score 0, 1 and 2 independently. Conclusion: MRI EPE is a straightforward tool that strongly correlates with the presence of pEPE. If validated prospectively, this scoring system could assist in counseling patients regarding nerve-sparing approach.
PURPOSE:To obtain a preventing and therapeutic agent for allergic diseases containing polygalacturonic acid which is a common substance in a pectate lyase and a polygalacturonase, its salt or ester as an active ingredient. CONSTITUTION:This preventing and therapeutic agent for allergic diseases contains polygalacturonic acid, its salt or ester as an active ingredient. The agent is useful as a preventing and therapeutic agent for pollinosis, among them pollinosis of Cryptomeria japonica D. Don. The preventing and therapeutic agent is capable of preventing and treating the allergic diseases by inhibiting the formation of a cross-linked structure of an allergen with IgE on the surface of sensitized cells. The polygalacturonic acid may be a polyuronic acid comprising a galacturonic acid residue; however, pectic acid in which naturally occurring D-galacturonic acid is bound through a 1   4 bonds is especially preferred. An alkaline metallic salt such as an Na or a K salt, an alkaline earth metallic salt, an organic amine salt, etc., are cited as the salt. A methyl, an ethyl esters, etc., are cited as the ester.
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with the incidence of about 70/100,000 in China. Recurrent relapses of disease and development of long-term organ damage are two key unsolved clinical problems. Its pathogenesis is still unclear, but B cells have been confirmed to play a vital role in it. Belimumab, a B-lymphocyte stimulating factor (Blys) inhibitor, was the only FDA-approved biological agent for SLE. BLISS-52 showed that more active lupus patients had their SELENA-SLEDAI score reduced by at least 4 points during 52 weeks with belimumab 10 mg/kg (58% vs 46%, p=0·0024) than with placebo. But there was limited data about belimumab in SLE patients with low disease activity. Our previous study indicated that even these patients still have an annual flare rate of 30-40%. Therefore, we try to explore whether low-dose of belimumab could prevent the disease flares in SLE patients with low disease activity.
Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
252,678. Smalpage, E. S. H. May 27, 1925, [Convention date]. Void [Published under Sect. 91 of the Acts]. Antitoxins and toxins. - Antitoxic serums are prepared by mixing bacilli with a bacteriolytic agent or enzyme obtained by extracting the spleen or lymph gland tissue of an animal, filtering the toxic solution so obtained to remove the granulated bacilli, injecting a horse or other animal with the toxic solution, and obtaining antitoxic serum from the blood of the animal. The bacteriolytic agent is prepared by macerating the spleen or gland tissue in alcohol or water, filtering, treating the filtrate to remove fats, proteins, salts and lipoids by precipitation &c.. and concentrating the solution by evaporation. Bacilli specified are those of tuberculosis and typhoid fever, and it is stated that the gland' extract will destroy also " protein cleavage growths, substances, or products."
The primary objective of this study was to compare short-term outcomes between Intracorporeal ileocolic anastomosis (IIA) and extracorporeal ileocolic anastomosis (EIA) after laparoscopic right hemicolectomy in patients with visceral obesity. The secondary objective was to identify risk factors associated with prolonged postoperative ileus (PPOI) after laparoscopic right hemicolectomy. This single-center retrospective study analyzed visceral obesity patients who underwent laparoscopic right hemicolectomy for primary bowel cancer between January 2020 and June 2023. Patients were categorized into IIA and EIA groups based on the type of anastomosis, and a 1:1 propensity score-matched analysis was performed. A total of 129 patients were initially included in this study, with 45 patients in each group following propensity score matching. The IIA group had significantly longer anastomosis times (p < 0.001), shorter incision length (p < 0.001), and shorter length of stay (p = 0.003) than the EIA group. Meanwhile, the IIA group showed a shorter time to first flatus (p = 0.044) and quicker tolerance of a solid diet (p = 0.030). On multivariate analysis, postoperative use of opioid analgesics is an independent risk factor for PPOI (OR: 3.590 95% CI 1.033-12.477, p = 0.044), while IIA is an independent protective factor (OR: 0.195 95% CI 0.045-0.843, p = 0.029). IIA remains a safe and feasible option for visceral obesity patients. It is also associated with a quicker recovery of bowel function and shorter length of stay when compared to EIA. Additionally, IIA is an independent protective factor for PPOI.
<P>PROBLEM TO BE SOLVED: To provide a non-swelling mica powdery material without having creaking or rough feeling, having a good sliding property and a very good use feeling.  <P>SOLUTION: The surface-treated non-swelling synthetic mica powdery material is characterized by surface-treating a non-swelling synthetic mica powder material with an ammonium cationic surfactant, and having ≤0.25 dynamic frictional coefficient and ≥120° contact angle with water. After heat-treating the non-swelling synthetic mica powdery material at 600-1,350°C, the surface-treated material is obtained by bringing the material into contact with the ammonium cationic surfactant in an aqueous solvent. By heat-treating before the surface-treatment, the non-swelling synthetic mica powdery material having a very high water repellency and use feeling is obtained. By using the ammonium cationic surfactant and a higher fatty acid together, the water repellency and use feeling are further improved. It is suitable to use 0.1-5 mass% ammonium cationic surfactant and 0.1-5 mass% higher fatty acid.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
ABSTRACT OF THE DISCLOSURE     COMPOSITE WOUND DRESSING       The multilayered composite wound dressing comprises of a semipermeable membrane, a permeable supporting and reinforcing layer, and a non-stick, self-sealing biodegradable tissue interface. The semipermeable membrane may be synthetic collagen, an alginate or a biocompatible polymer and it controls the rate of water vapour transmission from the wound surface. The permeable supporting and reinforcing layer provides mechanical strength and is usually a textile fabric which may also be made electrically conductive by coating it with a carbon-doped silicon or natural rubber or depositing metal on the fabric. Alternatively, an activated carbon cloth fabric can also be used. The biodegradable tissue interface may be synthetic collagen, sodium-calcium alginate or collagen-alginate complex, and it provides non-stick haemostatic sealing and aids the wound repair processes. For topical medication, growth promoting, antibacterial, anti-allergic and therapeutic agents may also be incorporated.        The conductive supporting and reinforcing layer can be used to provide electrical charge transfer and stimulation of the wound using external fields which has been shown to enhance the wound healing process, produce post-operative pain relief and bacterial-inhibition. The composite wound dressing has application inter alia in treating general surgical wounds, burns, bedsores, infected ulcers, donor sites for skin grafts or alternatively can be used for electrode dressing in transcutaneous and functional stimulation.
The purpose of this pilot project is to test effectiveness of a tobacco-treatment cessation intervention (American College of Obstetricians and Gynecologists (ACOG) 5 A's) through use of a non-physician healthcare champion from within the clinic's existing infrastructure. This Tobacco use in Pregnancy Intervention for Cessation (ToPIC) will involve training the identified healthcare provider to become a Certified Tobacco Treatment Specialist (CTTS) and to administer the 5 A's to pregnant Medicaid patients receiving prenatal care through two high-volume Kentucky obstetrics clinics. This trial will provide evidence to evaluate this approach to delivering an established intervention in clinical practice.

The Investigators propose to test the effectiveness of the clinical intervention by using a two-armed cluster randomized controlled design. Eligible participants will be randomized to the intervention (ToPIC) or standard of care for smoking cessation in pregnancy. This pilot project will gather quantitative and qualitative data for a mixed-method, multi-stakeholder process evaluation of intervention training and delivery. Furthermore, the Investigators' use of Medicaid claims data to examine healthcare utilization outside of maternal and infant well-care visits will enhance understanding of the strengths and limitations of these data for future evaluations. This study has the potential to significantly impact the most vulnerable in Kentucky, where rates of tobacco use among pregnant women are among the highest in the nation.
Breastfeeding is a natural physiological process but initial critical step on a child s path to a healthy future. Breastfeeding is beneficial to mother, child and society. For this purpose WHO Re-established global breastfeeding culture to promote exclusive breastfeeding (EBF) up-to first 6 months of life 50% by year 2025.Globally Among primiparous 33% mothers experienced breastfeeding problems in first two weeks postpartum. Determinants of premature termination of EBF are nipple soreness, inadequate latch techniques, breast engorgement, and lack of educative supportive system on preventive measures. In Pakistan IMR rate is 55.77% in 2022, major cause is failure to initiate and continuity in breast feeding. Infants get EBF 48% limited to 3 month. One of the significant factor is sore nipples that preeminent by the poor latch contributing 72%, secondary to infants improper sucking. It is hypothesized that ensuring sustain breast feeding by implementing the Planned, educational supportive training sessions, close observation to identify latch related problems and correct them promptly to prevent from nipple soreness, and predict for EBF. The aim of study to determine effectiveness of educational and hand on practice breastfeeding training session to prevent breastfeeding problems that ensure successful breastfeeding journey. Rational of this study is objectively assess the breastfeeding status and take corrective measure before problem become complicated by giving educational breastfeeding training session on preventive basis. However least literature existed on such preventive basis training sessions in countries that have high IMR. The study design will be "Randomized Control Trial." Sample size will comprise of 60 Participants 30 in control and 30 in interventional. Study participants will be selected by non-probability purposive sampling design and allocated in control group and interventional group by Simple Random sampling technique. After signing the informed consent form by participants Demographical data will be elicited. Nipple soreness rating scale and LATCH scoring system will be used to assess the feeding status. Observations will be recorded. SPSS will be used for data analysis and results compare between groups. Independent sample t test will be used to compare the effects of post test score of educational breastfeeding training session. Repeated measure of ANOVA will be used to compare differences between interventional group and control group for weekly follow up if data is normally distributed. A p-value of \<0.05 will be considered statistically significant. Outcome utilization of this study, Participants may use independently breastfeeding skills and achieve sustain breastfeeding process. Health care Administrator may make a policy to implement LATCH charting system, (like APGAR score). LATCH scoring system may include in nursing and medical education. Limitations of this study may use limited sample size and lack of follow-ups of infant up-to 6 months. More studies may need to confirm the findings for long term benefits of such training session
BACKGROUND: Recurrent ventral hernia repair can be challenging due to scarred tissue planes and the increasing complexity of disease related to multiple recurrences. Given the challenges of acquiring complete and accurate prior operative reports, surgeons often rely on computed tomography (CT) scans to obtain information and plan for re-operation. Still, the contribution of CT scans and the ability of surgeons to interpret them is controversial. Previously, we examined the ability of surgeons to determine prior operative techniques based on CT scans. Here, we assessed the accuracy of expert abdominal wall reconstruction (AWR) surgeons in identifying the type of prior mesh using CT imaging.
METHODS: A total of 22 highly experienced AWR surgeons were asked to evaluate 21 CT scans of patients who had undergone open ventral hernia repair with bilateral transversus abdominis release utilizing mesh. The surgeons were required to identify the mesh type from a multiple-choice selection. Additionally, negative controls (patients without a history of prior laparotomy) and positive controls (patients with laparotomy but no ventral hernia repair) were incorporated. The accuracy of the surgeons and interrater reliability was calculated.
RESULTS: The accuracy rate of the surgeons in correctly identifying the mesh type was 46%, with heavy-weight synthetic mesh (HWSM) being identified only 35.4% of the time, Strattice mesh and medium-weight synthetic mesh (MWSM) were identified at 46.3%, and 51.8%, respectively. The interrater reliability analysis found a moderate level of agreement 0.428 (95% CI 0.356-0.503), and the repeatability measure was poor-0.053 (95% CI 0-0.119); this indicates that surgeons cannot reliably replicate the identification process.
CONCLUSIONS: Surgeons' ability to accurately identify the type of previous mesh using CT scans is poor. This study underscores the importance of documenting the type of mesh used in the operative report and the need for standardized operative notes to improve the accuracy and consistency of documentation.
NEW MATERIAL:An anthracyclin substance shown by the formula. Melting point: 139-143 deg.C. Color: red. Solubility: soluble in methanol, ethanol, or chloroform, slightly soluble in water or hexane. pH: basicity. USE:An antitumor agent. Having strong growth inhibitory action on fibroblast M-MSV Balb 3T3 of mouse transformed with Moloney strain of Murine Sarcoma Virus. Having lower side effect than adriamycin, aclacinomycin A. PREPARATION:A novel strain Streptomyces cosmosus FERM P-7074(AJ 9450) is aerobically cultivated usually in a liquid medium at 4-9pH at 15-40 deg.C. A compound shown by the formula is obtained from the culture solution by combining well-known extraction with an organic solvent such as n-butanol, etc., adsorption chromatography, etc.
Systems and methods for camera control within surgical robotic systems are provided. One system includes a computing device, multiple robot assemblies, and a surgeon console. Each robot assembly among the multiple robot assemblies includes a robotic arm. A robotic arm of a first robot assembly is coupled to an image capture device. Robotic arms of at least a subset of robot assemblies, different from the first robot assembly, are coupled to surgical instruments. The surgeon console includes multiple handles, each communicatively coupled to a robot assembly coupled to a surgical instrument. The surgeon console is configured to transmit to the computing device one or more packets that include data related to a movement of at least one handle. The computing device configured to calculate a new position of the image capture device and transmit instructions to the first robot assembly to move the image capture device to the new position.
A randomized control trial will be conducted at IPMR (Institute of Physical Medicine and Rehabilitation) on 60 patients with non-specific neck pain with age group between 25-40 years. Initial screening of the patients will be carried out by referring physiatrist. Patients who fulfils inclusion criteria will be randomly allocated to either group by computer generated random sampling after taking written informed consent. All the patients will be evaluated using Visual analogue scale for pain, Neck disability index for functional status and disability, Universal goniometer for cervical range of motion and WHO BREF for quality of life on 1st and 6th sessions. Group 1 will receive Post isometric relaxation for Upper trapezius and levator scapulae along with Cryotherapy and strengthening exercises . Group 2 will receive myofascial release therapy for Upper Trapezius and Levator scapulae muscles along with cryotherapy and strengthening exercises. Data will be analyzed using the SPSS version 21. Baseline reading will be taken for further comparison at the end of treatment. Baseline variables are Pain, ROM, Functional disability and Qol. For within group analysis, paired sample t test will be used. For intergroup independent sample t test will be used. P value less than 0.05 will be set as threshold to detect statistical significance.
FIELD: medicine. SUBSTANCE: method involves crushing raw velvet antlers and/or coagulated blood and/or raw organs of velvet antlers deers to stuffing meat state. The matter is dried and comminuted at temperature not exceeding 60 C and 10-60 mm of mercury column rarefaction. Blood usable in preparing the biologically active product is taken with needle introduced into blood vessel and 50-450 mm of mercury column rarefaction is created. The so produced biologically active preparation is administered as baths. 0.1 to 5.02 units amount of preparation is diluted in 100-150 l of water at 36-38.5 C. The baths are to be taken daily during 5-10 days. The treatment is repeated 3-6 month later. EFFECT: wider raw material base for producing biologically active product of reindeer breeding; simplified and accelerated production method. 5 cl, 2 tbl
Double blind, randomised, Placebo and Standard Care controlled, single centre study. Each subject receives a total of 6 wounds, two incisions and four punch biopsies. Each subject serves as their own control, i.e. Arm 1 incisions/biopsies randomly received one of two treatments and Arm 2 incisions/biopsies received the same treatments as for Arm 1 but in reverse. The randomisation of the treatment allowed for control of possible positional effects on healing/scarring. Healed scars from incisional wounds excised from Arm 1 and Arm 2 after 6 months for histological analysis.
Disclosed is an isolated antibody, or functional fragment thereof, that specifically binds to a hLIGHT epitope wherein the antibody comprises: (a) i) a VH CDR 1 having the amino acid sequence of SEQ ID NO. 20; and ii) a VH CDR 2 having the amino acid sequence of SEQ ID NO. 21; and iii) a VH CDR 3 having the amino acid sequence of SEQ ID NO. 22; and (b) i) a VL CDR 1 having the amino acid sequence of SEQ ID NO. 35; and ii) a VL CDR 2 having the amino acid sequence of SEQ ID NO. 36; and iii) a VL CDR 3 having the amino acid sequence of SEQ ID NO. 37. Also disclosed is the use of the antibody for the manufacture of a composition for alleviating one or more symptoms of inflammatory bowel disease (IBD) in a human selected from abdominal cramps and pain, bloody diarrhea, severe urgency to have a bowel movement, fever, loss of appetite, weight loss, anemia, fatigue, and/or sores on lower legs, ankles, calves, thighs, and arms, profuse bleeding from intestinal ulcers, perforation or rupture of the bowel, strictures and obstruction, fistulae (abnormal passage) and perianal disease, toxic megacolon, and or malignancy of the colon or small intestine, arthritis, skin conditions, inflammation of the eye, liver and kidney disorders, and/or bone loss.
Relapsing remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis, affecting more than 80% of MS patients. RRMS is comprised of two phases: the auto-inflammatory episodes, in which the immune system is actively destroying myelin, alternate with remission phases. Currently there is no cure for this devastating disease. The present disclosure provides compositions and methods useful for inducing remyelination. The methods are useful for promoting remyelination to treat diseases and disorders such as MS. The present disclosure describes compositions and methods useful for inhibiting LRP1 activity. In one aspect, a siRNA against LRP1 can be used. It is disclosed that myelination can be regulated by inhibiting the interaction of LRP1 and p75NTR and that it inhibits activation of Rho-A.